Sugi Predict

Sugi Predict / Compounds / SCHEMBL563377

SCHEMBL563377

SCHEMBL563377

CC1CC(=O)N(C(C)C(N)=O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA3 P07451 1/20 0.33
▸ CA4 P22748 1/20 0.33
▸ CA6 P23280 1/20 0.33
▸ CA5A P35218 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ CA13 Q8N1Q1 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ CA5B Q9Y2D0 1/20 0.33
▸ POLB P06746 3/20 0.33
▸ APEX1 P27695 1/20 0.32
▸ BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11623232 0.82 APEX1 (0.46) MAPTKMT2AMEN1LMNACA12
SCHEMBL2617930 0.81 MEN1 (0.34) MAPTKMT2AMEN1
SCHEMBL25626554 0.81 MAPT (0.39) MAPTKMT2ALMNACA12CA1
SCHEMBL563231 0.79 CA1 (0.53) MAPTKMT2ALMNACA12CA1
SCHEMBL10239611 0.79 CA1 (0.53) MAPTKMT2ALMNACA12CA1
SCHEMBL563865 0.78 BRD4 (0.50) MAPTKMT2AMEN1LMNACA12
SCHEMBL563681 0.77 MAPT (0.39) MAPTKMT2AMEN1LMNACA12
SCHEMBL563551 0.77 MAPT (0.39) MAPTKMT2AMEN1LMNACA12
SCHEMBL564518 0.77 MAPT (0.39) MAPTKMT2AMEN1LMNACA12
SCHEMBL3751829 0.77 MAPT (0.57) MAPTKMT2ALMNAL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399033-B2 Oligomer-containing pyrrolidine compounds NEKTAR THERAPEUTICS (US) 2016-07-26 — — US disclosed
US-20150366842-A1 OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS NEKTAR THERAPEUTICS 2015-12-24 — — US disclosed
US-9096517-B2 Oligomer-containing pyrrolidine compounds NEKTAR THERAPEUTICS (US) 2015-08-04 — — US disclosed
US-9096517-B2 Oligomer-containing pyrrolidine compounds NEKTAR THERAPEUTICS (US) 2015-08-04 — — US disclosed
US-20140288315-A1 OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS NEKTAR THERAPEUTICS 2014-09-25 — — US disclosed
US-20140288315-A1 OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS NEKTAR THERAPEUTICS 2014-09-25 — — US disclosed
US-8785661-B2 Oligome-containing pyrrolidine compounds NEKTAR THERAPEUTICS (US) 2014-07-22 — — US disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 — — US disclosed
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Biopharma SRL (BE) 2012-02-09 — — US disclosed
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 — — US disclosed
WO-2010132693-A2 OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS NEKTAR THERAPEUTICS (US) 2010-11-18 — — WO disclosed
WO-2010132693-A2 OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS NEKTAR THERAPEUTICS (US) 2010-11-18 — — WO disclosed
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2010-09-02 — — US disclosed
US-7692028-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2010-04-06 — — US disclosed
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2008-04-24 — — US disclosed
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses DIFFERDING EDMOND (BE) 2005-08-04 — — US disclosed
US-6911461-B2 For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse UCB, S.A. (BE) 2005-06-28 — — US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 — — US disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 MAPT 957/4885KMT2A 1072/4885MEN1 1354/4885
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 MAPT 957/4885KMT2A 1072/4885MEN1 1354/4885
US-20150366842-A1 OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS HTT, PML, NOD2 MAPT 19/4885KMT2A 3743/4885MEN1 1449/4885
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 MAPT 957/4885KMT2A 1072/4885MEN1 1354/4885
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES CYP1B1, OGDH, CYP1A2 MAPT 957/4885KMT2A 1072/4885MEN1 1354/4885
US-20140288315-A1 OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS HTT, PML, NOD2 MAPT 19/4885KMT2A 3743/4885MEN1 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.